Literature DB >> 28707121

Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.

Hugo J A Adams1, Thomas C Kwee2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28707121     DOI: 10.1007/s00259-017-3771-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  22 in total

1.  18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

Authors:  Juliano J Cerci; Luís F Pracchia; Camila C G Linardi; Felipe A Pitella; Dominique Delbeke; Marisa Izaki; Evelinda Trindade; José Soares; Valeria Buccheri; José C Meneghetti
Journal:  J Nucl Med       Date:  2010-08-18       Impact factor: 10.057

2.  Hodgkin lymphoma: an Australian experience of ABVD chemotherapy in the modern era.

Authors:  Azim Jalali; Francis J Ha; Geoff Chong; Andrew Grigg; Joe Mckendrick; Anthony P Schwarer; Rowan Doig; Anis Hamid; Eliza A Hawkes
Journal:  Ann Hematol       Date:  2016-02-15       Impact factor: 3.673

3.  The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

Authors:  Andrea Gallamini; Sally F Barrington; Alberto Biggi; Stephane Chauvie; Lale Kostakoglu; Michele Gregianin; Michel Meignan; George N Mikhaeel; Annika Loft; Jan M Zaucha; John F Seymour; Michael S Hofman; Luigi Rigacci; Alessandro Pulsoni; Morton Coleman; Eldad J Dann; Livio Trentin; Olivier Casasnovas; Chiara Rusconi; Pauline Brice; Silvia Bolis; Simonetta Viviani; Flavia Salvi; Stefano Luminari; Martin Hutchings
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

4.  Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.

Authors:  Charles Mesguich; Anne-Laure Cazeau; Krimo Bouabdallah; Pierre Soubeyran; Martine Guyot; Noël Milpied; Laurence Bordenave; Elif Hindié
Journal:  Br J Haematol       Date:  2016-08-19       Impact factor: 6.998

5.  The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma.

Authors:  Neta Goldschmidt; Omer Or; Martine Klein; Bella Savitsky; Ora Paltiel
Journal:  Ann Hematol       Date:  2010-08-13       Impact factor: 3.673

6.  End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma.

Authors:  J A Barnes; A S LaCasce; K Zukotynski; D Israel; Y Feng; D Neuberg; C E Toomey; E P Hochberg; G P Canellos; J S Abramson
Journal:  Ann Oncol       Date:  2010-10-15       Impact factor: 32.976

Review 7.  Hodgkin's lymphoma: the pathologist's viewpoint.

Authors:  S A Pileri; S Ascani; L Leoncini; E Sabattini; P L Zinzani; P P Piccaluga; A Pileri; M Giunti; B Falini; G B Bolis; H Stein
Journal:  J Clin Pathol       Date:  2002-03       Impact factor: 3.411

8.  Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.

Authors:  Peter Borchmann; Heinz Haverkamp; Andreas Lohri; Ulrich Mey; Stefanie Kreissl; Richard Greil; Jana Markova; Michaela Feuring-Buske; Julia Meissner; Ulrich Dührsen; Helmut Ostermann; Ulrich Keller; Georg Maschmeyer; Georg Kuhnert; Markus Dietlein; Carsten Kobe; Hans Eich; Christian Baues; Harald Stein; Michael Fuchs; Volker Diehl; Andreas Engert
Journal:  Lancet Oncol       Date:  2017-02-22       Impact factor: 41.316

9.  US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816.

Authors:  Oliver W Press; Hongli Li; Heiko Schöder; David J Straus; Craig H Moskowitz; Michael LeBlanc; Lisa M Rimsza; Nancy L Bartlett; Andrew M Evens; Erik S Mittra; Ann S LaCasce; John W Sweetenham; Paul M Barr; Michelle A Fanale; Michael V Knopp; Ariela Noy; Eric D Hsi; James R Cook; Mary Jo Lechowicz; Randy D Gascoyne; John P Leonard; Brad S Kahl; Bruce D Cheson; Richard I Fisher; Jonathan W Friedberg
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

10.  No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.

Authors:  Lasse H Jakobsen; Martin Hutchings; Peter de Nully Brown; Johan Linderoth; Karen J Mylam; Daniel Molin; Hans E Johnsen; Martin Bøgsted; Mats Jerkeman; Tarec C El-Galaly
Journal:  Br J Haematol       Date:  2016-02-05       Impact factor: 6.998

View more
  1 in total

1.  Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".

Authors:  Elif Hindié; Charles Mesguich; Krimo Bouabdallah; Noël Milpied
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-10       Impact factor: 9.236

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.